Study Title
BlinFant: A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
Protocol ID
NL59901.078.17 (BlinFant)
Condition/s
Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage
New diagnosis
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Princess Maxima Center for Pediatric Oncology & Utrecht
Princess Maxima Center for Pediatric Oncology & Utrecht
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Pilot
Age Eligibility
<12 months
ANZCTR
ACTRN12620000542998
| Study Title | BlinFant: A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network) |
|---|---|
| Protocol ID | NL59901.078.17 (BlinFant) |
| Disease (Sub Disease) | Acute Lymphoblastic Leukaemia (ALL) |
| Diagnosis Stage | New diagnosis |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ Princess Maxima Center for Pediatric Oncology & Utrecht |
| Links | https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379482&isReview=true |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 20/07/2018 |
| Study Type | Treatment |
| Phase | Pilot |
| Age Eligibility | <12 months |
| ANZCTR | ACTRN12620000542998 |